No Data
No Data
ITeos To Present Preclinical Data On Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, And Novel PTPN1/2 Inhibitor At The AACR Annual Meeting 2025
Wall Street Analysts Think ITeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
ITeos Therapeutics: Poised for Success With Anti-TIGIT Therapies Amidst Competitive Landscape
J.P. Morgan Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $15
ITeos Therapeutics Price Target Cut to $15.00/Share From $22.00 by JP Morgan
ITeos Therapeutics Is Maintained at Overweight by JP Morgan